

蘇瑀 博士 (Dr. Yeu Su)

學歷：

台大藥學學士 1982

台大生化碩士 1984

美國 University of Wisconsin-Madison 分子生物學博士 1986 - 1991

經歷：

博士後研究 Johns Hopkins Oncology Center 1991 - 1993

副教授 陽明大學藥理所 1993 - 2000

副教授 陽明大學生藥所 2000 - 2004

教授 陽明大學生藥所 2005 - present

研究方向：

1. 大腸直腸癌癌化機轉之研究 (Dissecting the mechanism of human colorectal carcinogenesis)
2. 大腸直腸癌治療藥物之研發 (Discovery of drugs for colorectal cancer treatment)
3. 胸腺素 $\beta 4$ 生理及病理功能之研究 (Study of the physiological and pathological functions of thymosin $\beta 4$)

在陽明大學發表之論文：

1. Tang R.Y. and **Su Y.*** (1997) Construction of a cell-based high-flux assay for the rev protein of HIV-1. **J. Virol. Methods** 65: 153-158.
2. **Su Y.,*** Chang C.L., Lee S.S., Chen W.C. and Huang C.F. (1998) In vitro cytotoxic activity of 1-decarboxy-3-oxo-ceanothic acid in a human ovarian adenocarcinoma cell line. **Res. Comm. Mol. Pathol. & Pharmacol.** 100: 313-326.
3. Lee S.S., Chen W.C., Huang C.F. and **Su Y.** (1998) Preparation and cytotoxic effect of ceanothic acid derivatives. **J. Nat. Prod.** 61: 1343-1347.
4. **Su Y.,*** Chang S.L. and Hsiao H.L. (2000) Characterization of a 5'-flanking region supporting the transcription of mouse thymosin β -4 in mouse NIH3T3 cells. **Mol.Cell. Biochem.** 203: 163-167.
5. **Su Y.,*** Sun C.M., Chuang H.H. and Chang P.T. (2000) Studies on the cytotoxic mechanisms of ginkgetin in a human ovarian adenocarcinoma cell line. **Naunyn-Schmiedeberg's Arch. Pharmacol.** 362: 82-90.
6. Chang P.T. and **Su Y.*** (2000) Protocol for quantitative and qualitative analyses of in vitro aggregation of synthetic β -amyloid: a method applicable to the

identification of substances that may have therapeutic efficacy for Alzheimer's disease. **Brain Res. Protocols.** 6: 6-12.

7. **Su Y.*** and Chang P.T. (2001) Acidic pH promotes the formation of toxic fibrils from β -amyloid peptides. **Brain Res.** 893: 287-291.
8. Lai G.H., Chen C.F., **Su Y.**, Ho L.T. and Lin A.M. (2001) Lack of protective effect by intermittent hypoxia on MPTP-induced neurotoxicity in mice. **Ann. NY Acad. Sci.** 939: 33-44.
9. **Su Y.*** and Lee H.R. (2002) A high-throughput system for identifying human interleukin-2 inducers and/or repressors based on the expression of a reporter gene in Jurkat T cells. **Anal. Biochem.** 303: 202-206.
10. Wang W-S, Chen P-M, Hsiao H-L, Ju S-Y. and **Su Y.*** (2003) Overexpression of the thymosin β -4 gene is associated with malignant progression of SW480 colon cancer cells. **Oncogene** 22: 3297-3306.
11. Wang W-S, Chen P-M, Hsiao H-L, Wang W.S., Chen P.M., Hsiao H.L., Wang H.S., Liang W.Y. and **Su Y.*** (2004) Overexpression of the thymosin β -4 is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma. **Oncogene** 23: 6666-6671.
12. Lee O.K., Ko Y.C., Kuo T.K., Chou S.H., Li H.J., Chen W.M., Chen T.H. and **Su Y.*** (2004) Fluvastatin and lovastatin but not pravastatin induce neuroglial differentiation in human mesenchymal stem cells. **J. Cell Biochem.** 93: 917-928.
13. Sun K.H., Sun G.H., **Su Y.**, Chang C.I., Chuang M.C., Wu W.L., Chu C.Y. and Tang S.J. (2004) Acidic-rich region of amyloid precursor protein induces glial cell apoptosis. **Apoptosis** 9: 833-841.
14. Yang F.L., Lu C.P., Chen C.S., Chen M.Y., Hsiao H.L., **Su Y.**, Tsay S.S., Zou W and Wu S.H. (2004) Structural determination of the polar glycolipids from thermophilic bacteria *Meiothermus taiwanensis*. **Eur. J. Biochem.** 271: 4545-4551.
15. Hsiao H.L. and **Su Y.*** (2005) Identification of the positive and negative cis-elements involved in modulating the constitutive expression of mouse thymosin β -4 gene **Mol. Cell Biochem.** 272: 75-84.
16. Yang S.P., Li H.J. and **Su Y.*** (2005) Molecular cloning and structural characterization of the functional human thymosin β -4 gene. **Mol. Cell Biochem.** 272: 97-105.
17. Hsiao H.L., Wang W.S., Chen P.M. and **Su Y.*** (2006) Overexpression of thymosin β -4 renders SW480 colon carcinoma cells more resistant to apoptosis triggered by FasL and two topoisomerase II inhibitors via downregulating Fas and upregulating Survivin expression, respectively. **Carcinogenesis** 27: 936-944.

18. Wang W.S., Chen P.M. and **Su Y.*** (2006) Colorectal carcinoma: from tumorigenesis to treatment. **Cell. Mol. Life Sci.** 63: 663-71. (Review article)
19. Wang W.S., Chen P.M., Wang H.S., Liang W.Y. and **Su Y.*** (2006) Matrix metalloproteinase-7 increases resistance to Fas- mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. **Carcinogenesis** 27: 1113-1120.
20. Huang S.C., Hu C.H. Tang, M.C., Wang W.S., Chen P.M. and **Su Y.*** (2007) Thymosin β -4 triggers an epithelial-mesenchymal transition in colorectal carcinoma by upregulating integrin-linked kinase. **Oncogene** 26: 2781-2790.
21. Ho J.H., Chuang C.H., Ho C.Y., Shih V.Y., Lee O.K. and **Su Y.*** (2007) Internalization is essential for the anti-apoptotic effects of exogenous thymosin β -4 on human corneal epithelial cells. **Invest. Ophthalmol. Vis. Sci.** 48: 27-33.
22. Lien C.Y., Lee O.K. and **Su Y.*** (2007) Cbfb enhances the osteogenic differentiation of both human and mouse mesenchymal stem cells induced by Cbfa-1 via reducing its ubiquitination-mediated degradation. **Stem Cells** 25: 1462-1468.
23. Wang W.S., Chen P.M., Chiou T.J., J.H. Liu J.H., .Ho C.T, Lin J.K., Lin, T.C., Wang H.S., Liang W.Y. and **Su Y.*** (2007) The R497K polymorphism of EGFR is a favorable prognostic factor for patients with colorectal carcinoma. **Clin. Cancer Res.** 13: 3597-3604.
24. Lee H.J., **Su Y.**, Lui W.Y., Chau G.Y., Yin P.H., Lee H.C. and Chi C.W. (2008) Peroxisome proliferator-activated receptor gamma coactivator-1a (PGC-1a) upregulated E-cadherin expression in HepG2 cells. **FEBS Lett.** 582: 627-634.
25. Ho H.C., Tseng K.C., Ma W.H., Chen K.H., Lee O.K. and **Su Y.*** (2008) Thymosin β -4 upregulates anti-oxidative enzymes and protects human cornea epithelial cells against oxidative damage. **Br. J. Ophthalmol.** 92: 992-997.
26. Lien C.Y., Ho C.Y., Lee O.K., Blunn G.W. and **Su Y.*** (2009) Restoration of bone mass and strength in glucocorticoid-treated mice by systemic transplantation of CXCR4 and Cbfa-1 co-expressing mesenchymal stem cells. **J. Bone Miner. Res.** 24: 837-848.
27. Lee H.J., **Su Y.**, Yin P.H., Lee H.C. and Chi C.W. (2009) PPAR(gamma)/PGC-1(alpha) pathway in E-cadherin expression and motility of HepG2 cells. **Anticancer Res.** 29: 5057-5063.
28. Ho J.H., Ma W.H., **Su Y.**, Tseng K.C., Kuo T.K. and Lee O.K. (2010) Thymosin β -4 directs cell fate determination of human mesenchymal stem cells through biophysical effects. **J. Orthop. Res.** 28: 131-138.

29. Ho J.H., **Su Y.**, Chen K.H., Lee O.K. (2010) Protection of thymosin β -4 on corneal endothelial cells from UVB-induced apoptosis. **Chin J Physiol.** 53: 190-195.
30. Tang M.C., Chan L.C., Yeh Y.C., Chen C.Y., Chou T.Y. and **Su Y.*** (2011) Thymosin β -4 induces colon cancer cell migration and clinical metastasis via enhancing ILK/IQGAP1/Rac1 signal transduction pathway. **Cancer Lett.** 308: 162-171.
31. Tang M.C. and **Su Y.*** (2011) Thymosin β 4 knockdown disrupts mitochondrial functions SW480 human colon cancer cells. **Cancer Sci.** 102: 1665-1672.
32. Huang Y.F., Lin J.J., Lin C.H. **Su Y.*** and Hung S.C.* (2012) c-Jun N-terminal kinase 1 negatively regulates osteoblastic differentiation induced by BMP-2 via phosphorylation of Runx2 at Ser104. **J. Bone Miner. Res.** 27: 1093-1105.
33. Weng J.J. and **Su Y.*** (2013) Nuclear matrix-targeting of the osteogenic factor Runx2 is essential for its recognition and activation of the alkaline phosphatase gene. **Biochim Biophys Acta.** 1830: 2839-2852.
34. Dieudonne F.X., S ev ere N., Bioso-Duplan M., Weng J.J., **Su Y.** and Marie P.J. (2013) Promotion of osteoblast differentiation in mesenchymal cells through Cbl-mediated control of STAT5 activity. **Stem Cells** 31: 1340-1349.
35. Ju SY, Chiou SH. and **Su Y.*** (2013) Maintenance of the stemness in CD44⁺ HCT-15 and HCT-116 human colon cancer cells requires miR-203 suppression. **Stem Cell Res.** 12: 86-100.
36. Chao T.C., Chen K.J., Tang M.C., Chan L.C., Chen P.M., Tzeng C.H. and **Su Y*** (2014) Thymosin β 4 knockdown in IEC-6 normal intestinal epithelial cells induces DNA re-replication via downregulating Emi1. **J. Cell Physiol.** 229, 1639-1646.
37. Chao T.C., Chan L.C., Ju S.Y., Tang M.C., Chen P.M., Tzeng C.H. and **Su Y*** (2014) In vivo growth of CT-26 mouse colorectal cancer cells can be suppressed by the infection of the adenoviruses expressing a small hairpin RNA targeting specifically on thymosin β 4 mRNA. **Cancer Gene Ther.** 21, 389-396.
38. Ju S.Y., Huang C.Y. F., Huang W. C. and **Su Y*** (2015) Identification of Thiostrepton as a novel therapeutic agent that targets human colon cancer stem cells. **Cell Death Dis.** July 2nd.

Manuscript submitted

Chen M.H., Weng J.J, Cheng C.T., Wu R.C., Huang S.C., Wu J.E., Liu C.Y., Chang M.H.P., Chen M.H., Chiang K.C., Yeh T.S., **Su Y*** and Yeh C.N.* ALDH1A3, the major aldehyde dehydrogenase isoform in human cholangiocarcinoma cells, affects prognosis and gemcitabine resistance in CCA patients. **J Hepatol.**

已畢業之博士生 (Ph.D.)

1. 張佩德 (Pei-Teh Chang); Institute of Pharmacology, NYMU; July 2002
Study of the pathophysiological properties of A β aggregates and the protective mechanisms of EGb761 against the cytotoxicity of A β aggregates on PC12 cells
2. 王緯書* (Wei-Shu Wang); Institute of Clinical Medicine, NYMU; Dec. 2004
Overexpression of the Thymosin β -4 gene is associated with malignant progression of SW480 colon cancer cells and the distant metastasis of human colorectal carcinoma
*陽明大學醫學系教授 兼 附設醫院 醫療副院長 (Professor of the Department of Medicine of NYMU & Medical Deputy Superintendent of NYMU-Hospital)
3. 蕭宏良 (Hung-Liang Hsiao); Institute of Pharmacology, NYMU; Jan. 2006
Analyzing the promoter activity of Thymosin β 4 gene and the effect of overexpression of Thymosin β 4 on apoptosis of SW480 colon cancer cells
4. 黃曉春 (Hsiao-Chun Huang); Institute of Biosci & Biotech, NTOU; Nov. 2006
Thymosin β 4 triggers an epithelial-mesenchymal transition in colorectal carcinoma by upregulating integrin-linked kinase
5. 連君洋 (Chun-Yang Lien); Institute of Biopharm Sciences, NYMU; June 2007
Assessment of the efficacy of systemic transplantation of the ex vivo manipulated mesenchymal stem cells in bone regeneration therapy
6. 何慧君⁺ (Hui-Chun Ho); Institute of Biopharm Sciences, NYMU; May, 2008
Elucidation of the anti-apoptotic mechanisms of exogenous Thymosin β 4 on human corneal epithelial cells
⁺台北醫學大學 臨醫所副教授 兼 萬芳醫院 幹細胞中心主任 (Associate Professor of the Graduate Institute of Clinical Medicine of Taipei Medical University & Director of the Stem Cell Center of Wan-Fang Hospital)
7. 唐美娟 (Mei-Chuan Tang); Institute of Biopharm Sciences, NYMU; June 2011
The role of thymosin β 4 in actin cytoskeleton and mitochondrial regulation in human colon cancer cells
8. 黃怡鳳 (Yi-Feng Huang); Institute of Biopharm Sciences, NYMU; Feb. 2012
The role of c-Jun N-terminal kinase 1 (JNK1) in BMP-induced osteoblastic differentiation
9. 翁靖傑 (Jing-Jie Weng); Institute of Biopharm Sciences, NYMU; Jan. 2013
Elucidating the mechanisms of transcription factor Runx2 in promoting osteogenic differentiation of mesenchymal stem cells and malignant progression of breast cancer cells
10. 朱思遠 (Sy-Yeuan Ju); Institute of Biopharma Sciences, NYMU; Jan. 2014
Elucidation of the role of CD44 in colon cancer stem cells derived from HCT-15 and HCT-116 lines and identification of drugs targeting this population

11. 趙大中[#] (Ta-Chung Chao); Institute of Clinical Medicine, NYMU; Dec. 2014
Assessment of the therapeutic potential in colorectal cancer as well as the
influences on normal intestinal epithelial cells of thymosin beta-4 knockdown

[#]台北榮總血液腫瘤科 主治醫師

就讀中之博士生

曾文科 (Wen-Ko Tseng, MD) Program in Molecular Medicine, NYMU